Interpace Biosciences, INC
Market Movers (8-K)
OID
Interpace Biosciences announced first quarter 2026 financial results, reporting $9.0 million in revenue and $0.8 million in income from continuing operations, with a 12% year-over-year increase in thyroid revenue.
OID
Interpace Biosciences announced its fourth quarter and full year 2025 financial results, highlighting strong thyroid segment growth and a significant non-cash tax benefit.
Better than expected
OID
Interpace Biosciences announced preliminary 2025 thyroid testing revenue growth of 21%, initiated 2026 guidance, converted all preferred stock, and plans a Nasdaq uplisting.
Better than expected
OID
Interpace Biosciences announced the early repayment of its term loan facility with BroadOak Capital Partners, enhancing financial flexibility and supporting future growth.
Better than expected
OID
Interpace Biosciences announced its third quarter 2025 financial results, highlighting record thyroid test volumes and revenue, alongside improved cash collections and operational efficiencies.
Better than expected
OID
Interpace Biosciences reports a 23% revenue decrease in Q2 2025 due to PancraGEN wind-down, but sees record thyroid test volume and revenue growth.
Worse than expected
Quarterly Earnings (10-Q)
OID
Interpace Biosciences reports a significant revenue decline and net income drop in Q3 2025, primarily due to the loss of Medicare coverage for its PancraGEN test, despite improving liquidity and reducing debt.
Worse than expected
Delay expected
Capital raise
OID
Interpace Biosciences reported a net loss of $0.64 million in Q2 2025, primarily due to the loss of Medicare reimbursement for its PancraGEN test and associated restructuring costs.
Worse than expected
Delay expected
Capital raise
OID
10-Q: Interpace Biosciences Reports Q1 2025 Results: Revenue Up, Faces PancraGEN Reimbursement Challenges
Interpace Biosciences reports increased revenue for Q1 2025 but faces challenges due to the loss of Medicare coverage for its PancraGEN test.
Worse than expected
Delay expected
Capital raise
OID
Interpace Biosciences saw a significant increase in revenue and a return to profitability in the third quarter of 2024, driven by higher test volumes.
Better than expected
Capital raise
OID
Interpace Biosciences reported a significant increase in revenue and operating income for the second quarter of 2024, driven by higher test volumes.
Better than expected
Capital raise
OID
Interpace Biosciences saw a 4% increase in revenue to $10.3 million in the first quarter of 2024, driven by higher test volumes.
Better than expected
Capital raise
Annual Reports (10-K)
OID
Interpace Biosciences filed an amendment to its 2025 Annual Report to include required proxy statement disclosures.
Delay expected
OID
Interpace Biosciences reports a significant net income increase in 2025 driven by a tax benefit, despite an 18% revenue decline following the discontinuation of its PancraGEN test.
Worse than expected
Capital raise
OID
Interpace Biosciences files an amendment to its 2024 Annual Report on Form 10-K to include information that was to be incorporated by reference from the company's definitive proxy statement.
OID
10-K: Interpace Biosciences Restates Financials Amid PancraGEN Uncertainty, Eyes Strategic Alternatives
Interpace Biosciences restates prior financial statements due to royalty accrual errors and navigates challenges including a potential non-coverage decision for its PancraGEN test.
Worse than expected
Capital raise
Delay expected
OID
10-K/A: Interpace Biosciences Files Amended 10-K to Include Missing Proxy Information and Certifications
Interpace Biosciences has filed an amendment to its annual report on Form 10-K to include information that was to be incorporated by reference from the company's definitive proxy statement and additional certifications.
Delay expected
OID
Interpace Biosciences achieved profitability in 2023, reporting operating income of $2.8 million, while navigating regulatory challenges and strategic shifts.
Better than expected
Capital raise
Insider Trading (Form 4)
OID
Ampersand 2018 Limited Partnership converted 28,000 shares of Series C Convertible Preferred Stock into 13,861,386 shares of Interpace Biosciences common stock.
OID
Christopher McCarthy, CFO of Interpace Biosciences, reports the vesting of restricted stock units and subsequent withholding of shares to cover tax obligations.
OID
Form 4: Interpace Biosciences Investor 1315 Capital II, L.P. Exchanges Series B Preferred Stock for Series C
1315 Capital II, L.P., a 10% owner of Interpace Biosciences, exchanged its Series B Convertible Preferred Stock for newly created Series C Convertible Preferred Stock on October 11, 2024.
OID
Ampersand 2018 Limited Partnership exchanged its existing shares of Interpace Biosciences Series B Preferred Stock for newly created Series C Convertible Preferred Stock on October 11, 2024.
Proxy Statements (Def-14A)
OID
Interpace Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for August 20, 2026, to be held virtually.
OID
Interpace Biosciences, Inc. has filed a definitive proxy statement with the SEC.
OID
Interpace Biosciences will hold its annual stockholders meeting virtually on November 12, 2024, to vote on the ratification of its independent accounting firm and other business matters.
Schedule 13G - Passive Investments
OID
Douglas M. Singer has filed an Amendment No. 4 to Schedule 13G, disclosing a beneficial ownership of 4.44% of Interpace Biosciences, Inc.'s common stock.
OID
Douglas M. Singer has filed an amended Schedule 13G, reporting beneficial ownership of 5.15% of Interpace Biosciences, Inc.'s common stock as of December 31, 2024.